Researchers have shown the possibility of using psilocybin -- the active compound in mushrooms with psychedelic properties -- as a therapeutic tool against mental disorders.
The study, published in The Lancet, suggests that additional 53 million cases of major depressive disorder and 76 million cases of anxiety disorders were due to the pandemic.
"We see a high excess mortality due to Covid-19 among the elderly with severe mental disorders, which gives us reason to consider whether this group should be given priority for vaccines," said researcher Martin Maripuu, Associate Professor
